Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models

BACKGROUND/AIMS: Efficient anti-fibrotic therapies are required for the treatment of liver cirrhosis. Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and cyclooxygenase-2 (COX-2) inhibitors have been reported to have anti-fibrotic effects. Here, we investigated whether combined treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Seong Hee, Yim, Hyung Joon, Hwang, Ji-won, Kim, Mi-jung, Lee, Young-Sun, Jung, Young Kul, Yim, Hyungshin, Kim, Baek-Hui, Park, Hae-Chul, Seo, Yeon Seok, Kim, Ji Hoon, Yeon, Jong Eun, Um, Soon Ho, Byun, Kwan Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271712/
https://www.ncbi.nlm.nih.gov/pubmed/35811365
http://dx.doi.org/10.3904/kjim.2021.138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271712/
https://www.ncbi.nlm.nih.gov/pubmed/35811365
http://dx.doi.org/10.3904/kjim.2021.138

Ejemplares similares